Metraipolis › archive › dc_5a8acc0705fa

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE) — Europe PMC PMID:36107966

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36107966
DOI
10.1371/journal.pone.0273914
License (as archived)
CC0-1.0
Archived
2026-10-16T14:45:05.369Z
SHA-256 of the archived text
03e66b883b92c9e7dfda4f24427b65fed1c72e38fb0dc9b375f60f27400b1066
Stable URL of this page
https://metraipolis.com/documento/dc_5a8acc0705fa

How to cite

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE) — Europe PMC PMID:36107966 — Europe PMC (en), https://europepmc.org/article/MED/36107966 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_5a8acc0705fa (Metraipolis archive dc_5a8acc0705fa, sha256 03e66b883b92c9e7dfda4f24427b65fed1c72e38fb0dc9b375f60f27400b1066)
BibTeX
@misc{dc5a8acc0705fa,
  title = {Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE) — Europe PMC PMID:36107966},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36107966},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_5a8acc0705fa; sha256 03e66b883b92c9e7dfda4f24427b65fed1c72e38fb0dc9b375f60f27400b1066},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36107966. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-09-15).
Identificativi: PMID 36107966 · PMCID PMC9477293 · DOI 10.1371/journal.pone.0273914.
Descrittori MeSH principali: Vaccines; COVID-19.
Pagina: https://europepmc.org/article/MED/36107966 — https://doi.org/10.1371/journal.pone.0273914. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-16T14:29:35.591Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.